Byondis B.V.

The phase III TULIP trial found trastuzumab duocarmazine (T-Duo) improved progression-free survival vs physician's choice in HER2-positive advanced breast cancer, though associated with ocular toxicity leading to higher discontinuation rates.

Lixte Biotechnology Holdings, Inc. schedules its 2024 Annual Meeting of Stockholders for December 19, 2024, to vote on the election of five director nominees, ratification of Weinberg & Company, P.A. as the independent registered public accounting firm, and approval of executive officer compensation. The meeting will be virtual, accessible via a live webcast.